We use our own and third party cookies to offer you our services, customize and analyze your browsing and show you advertising related to your preferences. By continuing to browse, we consider that you accept its use. You can change the settings and get more information in the
Treating premature bronchiolitis at Hospital Clínic
Reading time: 3 min
Hospital Clínic de Barcelona is committed to prevention in the treatment of bronchiolitis. Prevention is based on control measures to prevent infection, and prophylaxis by strengthening the immune system in patients who are at high risk of developing severe RSV bronchiolitis.
Hygiene measures are essential in controlling the disease, both at home and at healthcare centres.
Some measures to prevent RSV infection include:
Not exposing newborns to tobacco smoke, including during pregnancy.
Washing hands with soap and water before holding the baby.
Using disposable tissues, and throwing away used ones.
Cleaning toys more often when they are used by other children, as well as plates and bottles.
Preventing newborns coming into contact with people with fever or respiratory infections.
Breastfeeding should be the method of choice where possible, as it protects against respiratory infections.
Avoiding enclosed and potentially contagious environments, for example crowds.
Remember: if you notice any signs or symptoms, speak to your paediatrician as soon as possible.
Palivizumab for immunoprophylaxis
Humanised monoclonal antibodies against RSV are available for immunoprophylaxis. Palivizumab is a drug administered to newborns with risk factors in hospital. The indications for palivizumab were published in July 2008 in the Anales Españoles de Pediatría (Spanish Annals of Paediatrics) under the title “Consenso multidisciplinar español sobre la profilaxis de la infección respiratoria pediátrica por VRS” (Multidisciplinary consensus on prophylaxis of paediatric respiratory RSV infection in Spain).
Palivizumab prophylaxis recommended in the following cases:
Children under 2 years of age with bronchopulmonary dysplasia requiring treatment (oxygen supplements, bronchodilators, diuretics or corticosteroids) in the 6 months prior to the start of the RSV season, or who are discharged during the season.
Children under 2 years of age with congenital heart disease involving significant haemodynamic disorders, who are receiving treatment for heart failure, moderate or severe pulmonary hypertension or cyanogenic (cyanotic) heart disease.
Premature infants, born at the 28th week of pregnancy or before, who are 12 months of age or younger at the start of the RSV season.
Premature infants born between the 29th and 32nd weeks of pregnancy, who are 6 months of age or younger at the start of the RSV season.
Premature infants born between the 32nd and 35th weeks of pregnancy, who are younger than 6 months at the start of the RSV season, and who have two or more risk factors for hospitalisation due to RSV infection. These risk factors may include: not being breastfed, or being breastfed for less than 2 months, having at least one sibling of school age (up to 14 years), attending daycare, a family history of wheezing, crowded household conditions (living with 4 or more adults), malformations of the airways or neuromuscular disease.
Palivizumab is administered monthly via the intramuscular route for five months. It has been shown to reduce RSV hospitalisations among at-risk patients. Nevertheless, it has not been shown to reduce disease incidence, the duration of hospitalisation, or the use of oxygen therapy and mechanical ventilation. Nor does it reduce mortality. This is why it is important to maintain hygiene measures, even when this treatment is used.
Hospital Clínic has developed protocols, clinical practice guidelines and recommendations regarding the treatment and prevention of RSV.
Sorry this content wasn't helpful to you. Send us your comment and we will take it into account to continue improving.
Thanks for your help!
An error has occurred and we were unable to send your opinion, please try again later.
Substantiated information by:
Published: 14 September 2021
Updated: 14 September 2021
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.
Receive the latest updates related to this content.
Thank you for subscribing!
If this is the first time you subscribe you will receive a confirmation email, check your inbox
An error occurred and we were unable to send your data, please try again later.